全文获取类型
收费全文 | 15920篇 |
免费 | 782篇 |
国内免费 | 112篇 |
学科分类
医药卫生 | 16814篇 |
出版年
2021年 | 225篇 |
2020年 | 161篇 |
2019年 | 225篇 |
2018年 | 265篇 |
2017年 | 221篇 |
2016年 | 256篇 |
2015年 | 280篇 |
2014年 | 358篇 |
2013年 | 465篇 |
2012年 | 736篇 |
2011年 | 780篇 |
2010年 | 456篇 |
2009年 | 361篇 |
2008年 | 721篇 |
2007年 | 858篇 |
2006年 | 863篇 |
2005年 | 844篇 |
2004年 | 793篇 |
2003年 | 776篇 |
2002年 | 790篇 |
2001年 | 460篇 |
2000年 | 497篇 |
1999年 | 435篇 |
1998年 | 186篇 |
1997年 | 142篇 |
1996年 | 154篇 |
1995年 | 117篇 |
1994年 | 136篇 |
1993年 | 105篇 |
1992年 | 387篇 |
1991年 | 347篇 |
1990年 | 296篇 |
1989年 | 330篇 |
1988年 | 253篇 |
1987年 | 257篇 |
1986年 | 253篇 |
1985年 | 294篇 |
1984年 | 154篇 |
1983年 | 137篇 |
1982年 | 89篇 |
1981年 | 67篇 |
1979年 | 115篇 |
1978年 | 97篇 |
1977年 | 87篇 |
1974年 | 71篇 |
1972年 | 69篇 |
1971年 | 67篇 |
1969年 | 79篇 |
1968年 | 95篇 |
1966年 | 83篇 |
排序方式: 共有10000条查询结果,搜索用时 875 毫秒
1.
2.
N. Tanaka Y. Kunihiro R. Kawano T. Yujiri K. Ueda T. Gondo T. Matsumoto 《Clinical radiology》2021,76(1):50-59
3.
4.
Hideki Kobara Hirohito Mori Noriko Nishiyama Shintaro Fujihara Keiichi Okano Yasuyuki Suzuki Tsutomu Masaki 《Journal of gastroenterology and hepatology》2019,34(1):22-30
Rescue therapy for gastrointestinal (GI) refractory bleeding, perforation, and fistula has traditionally required surgical interventions owing to the limited performance of conventional endoscopic instruments and techniques. An innovative clipping system, the over‐the‐scope clip (OTSC), may play an important role in rescue therapy. This innovative device is proposed as the final option in endoscopic treatment. The device presents several advantages including having a powerful sewing force for closure of GI defects using a simple mechanism and also having an innovative feature, whereby a large defect and fistula can be sealed using accessory forceps. Consequently, it is able to provide outstanding clinical effects for rescue therapy. This review clarifies the current status and limitations of OTSC according to different indications of GI refractory disease, including refractory bleeding, perforation, fistula, and anastomotic dehiscence. An extensive literature search identified studies reported 10 or more cases in which the OTSC system was applied. A total of 1517 cases described in 30 articles between 2010 and 2018 were retrieved. The clinical success rates and complications were calculated overall and for each indication. The average clinical success rate was 78% (n = 1517) overall, 85% for bleeding (n = 559), 85% (n = 351) for perforation, 52% (n = 388) for fistula, 66% (n = 97) for anastomotic dehiscence, and 95% (n = 122) for other conditions, respectively. The overall and severe OTSC‐associated complications were 1.7% (n = 23) and 0.59% (n = 9), respectively. This review concludes that the OTSC system may serve as a safe and productive device for GI refractory diseases, albeit with limited success for fistula. 相似文献
5.
Fahrettin Covut Divya Gupta Raisa Pinto Nina Dambrosio Najla El Jurdi Howard Meyerson Masumi Ueda Merle Kolk Richard Creger Leland Metheny Brenda W. Cooper Paolo F. Caimi Ehsan Malek Folashade Otegbeye Hillard M. Lazarus Marcos De Lima Benjamin K. Tomlinson 《Clinical Lymphoma, Myeloma & Leukemia》2019,19(2):73-82
Introduction
Induction chemotherapy with cytarabine and an anthracycline (7+3) remains the standard of care for acute myeloid leukemia (AML).Patients and Methods
We retrospectively analyzed 183 newly diagnosed AML patients to compare the utility of rapid peripheral blast clearance (PBC), day of peripheral blast disappearance, residual blasts, and cellularity at day 14 bone marrow biopsy (D14BM) in predicting clinical response to 7+3 induction, overall survival (OS), and relapse-free survival (RFS).Results
In multivariable logistic regression analysis, day 2 PBC > 85% [P = .0016] was the only predictor of remission status, with sensitivity and specificity of 75%. Peripheral blast disappearance within 5 days after induction and < 10% cellularity in D14BM predicted superior OS and RFS in multivariate analysis. Median follow-up of patients was 28 months since diagnosis. Two-year OS and RFS for patients with ≤ 10% versus > 10% cellularity at D14BM was 60.6% [95% confidence interval (CI), 50.8%-72.2%] versus 32.5% [95% CI, 23.0%-45.8%], and 51.9% [95% CI, 41.9%-64.3%] versus 28.8% [95% CI, 19.1%-43.4%], respectively [P = .0003 for OS and .002 for RFS].Conclusion
Rapid PBC after 7+3 induction showed a significant improvement in specificity compared with D14BM, with similar sensitivity. Neither of these methods were reliably specific tools for the decision of early reinduction, despite their prognostic value. Our findings indicate that morphological cellularity in D14BM is an independent prognostic factor for OS and RFS, regardless of blast percentage, and that ≤ 10% cellularity defines D14BM hypoplasia. 相似文献6.
Takeshi Nagashima Ken Yamaguchi Kenichi Urakami Yuji Shimoda Sumiko Ohnami Keiichi Ohshima Tomoe Tanabe Akane Naruoka Fukumi Kamada Masakuni Serizawa Keiichi Hatakeyama Kenya Matsumura Shumpei Ohnami Koji Maruyama Tohru Mochizuki Masatoshi Kusuhara Akio Shiomi Yasuhisa Ohde Masanori Terashima Katsuhiko Uesaka Tetsuro Onitsuka Seiichiro Nishimura Yasuyuki Hirashima Nakamasa Hayashi Yoshio Kiyohara Yasuhiro Tsubosa Hirohisa Katagiri Masashi Niwakawa Kaoru Takahashi Hiroya Kashiwagi Masahiro Nakagawa Yuji Ishida Takashi Sugino Mitsuru Takahashi Yasuto Akiyama 《Cancer science》2020,111(2):687-699
This study aimed to establish the Japanese Cancer Genome Atlas (JCGA) using data from fresh frozen tumor tissues obtained from 5143 Japanese cancer patients, including those with colorectal cancer (31.6%), lung cancer (16.5%), gastric cancer (10.8%) and other cancers (41.1%). The results are part of a single‐center study called “High‐tech Omics‐based Patient Evaluation” or “Project HOPE” conducted at the Shizuoka Cancer Center, Japan. All DNA samples and most RNA samples were analyzed using whole‐exome sequencing, cancer gene panel sequencing, fusion gene panel sequencing and microarray gene expression profiling, and the results were annotated using an analysis pipeline termed “Shizuoka Multi‐omics Analysis Protocol” developed in‐house. Somatic driver alterations were identified in 72.2% of samples in 362 genes (average, 2.3 driver events per sample). Actionable information on drugs that is applicable in the current clinical setting was associated with 11.3% of samples. When including those drugs that are used for investigative purposes, actionable information was assigned to 55.0% of samples. Germline analysis revealed pathogenic mutations in hereditary cancer genes in 9.2% of samples, among which 12.2% were confirmed as pathogenic mutations by confirmatory test. Pathogenic mutations associated with non–cancerous hereditary diseases were detected in 0.4% of samples. Tumor mutation burden (TMB) analysis revealed 5.4% of samples as having the hypermutator phenotype (TMB ≥ 20). Clonal hematopoiesis was observed in 8.4% of samples. Thus, the JCGA dataset and the analytical procedures constitute a fundamental resource for genomic medicine for Japanese cancer patients. 相似文献
7.
Shogo Yamamoto Yutaka Midorikawa Genta Nagae Kenji Tatsuno Hiroki Ueda Mitsuhiko Moriyama Tadatoshi Takayama Hiroyuki Aburatani 《Cancer science》2020,111(2):601-609
Multiple hepatocellular carcinoma (HCC) is divided into two categories: intrahepatic metastasis (IM), which is a true relapse of HCC, and multicentric origin (MO), which is a second primary tumor. Clinical diagnosis of multiple HCC is usually made based on tumor location and/or time to recurrence; however, it is often difficult to distinguish the two types of multiple HCC. Using 41 matched pairs of multiple HCC specimens, we confirmed the accuracy of clinical diagnoses using exome sequence data and investigated the importance of discriminating the type of multiple HCC. Genomic analysis revealed that 18 (43.9%) patients diagnosed as having genomic IM had common mutations in a pair of HCC tumors with the main tumor of these patients being more progressive compared to those with genomic MO. The accuracy of clinical diagnosis based on lobe (Definition 1) and segment (Definition 2) were 68.3% and 78.0%, respectively. Intriguingly, recurrence ≥2 years after initial surgery for 3 patients was IM. The survival of patients with clinical IM was significantly shorter than for those with clinical MO based on both Definition 1 (P = 0.045) and Definition 2 (P = 0.043). However, mean survival was not different between the patients with genomic IM and those with MO (P = 0.364). Taken together, genomic analysis elucidated that liver cancer may spread more extensively and more slowly than previously thought. In addition, distinguishing multiple HCC as IM or MC may have provided biological information but was not of clinical importance with respect to patient prognosis. 相似文献
8.
Abe Takashi Yabuuchi Akiko Ezoe Kenji Skaletsky Helen Fukuda Junichiro Ueno Satoshi Fan Yuting Goldsmith Sierra Kobayashi Tamotsu Silber Sherman Kato Keiichi 《Journal of assisted reproduction and genetics》2020,37(2):297-304
Journal of Assisted Reproduction and Genetics - To determine age-adjusted overall success rates for patients undergoing clomiphene citrate only minimal stimulation cycle (mini) in vitro... 相似文献
9.
Heterozygous nonsense mutations near the C‐terminal region of IGF1R in two patients with small‐for‐gestational‐age‐related short stature 下载免费PDF全文
10.